The safety and tolerability of combined immune checkpoint inhibitors (anti-PD-1/PD-L1 plus anti-CTLA-4): a systematic review and meta-analysis

被引：0
|
作者：
Lihu Gu
Parikshit Asutosh Khadaroo
Hui Su
Liya Kong
Liangliang Chen
Xianfa Wang
Xinlong Li
Hepan Zhu
Xin Zhong
Junhai Pan
Manman Chen
机构：
[1] University of Chinese Academy of Sciences,Department of General Surgery, HwaMei Hospital
[2] Monash University School of Public Health and Preventive Medicine,Department of Surgical Oncology, HwaMei Hospital
[3] Zhejiang Chinese Medical University,Department of General Surgery
[4] University of Chinese Academy of Sciences,undefined
[5] Zhejiang University School of Medicine Sir Run Run Shaw Hospital,undefined
[6] Affiliated Hospital of Medical School Ningbo University and Ningbo City Third Hospital,undefined
来源：
BMC Cancer | / 19卷
关键词：
PD-1; PD-L1; CTLA-4; Adverse events; Meta-analysis;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] The safety and tolerability of combined immune checkpoint inhibitors (anti-PD-1/PD-L1 plus anti-CTLA-4): a systematic review and meta-analysis
    Gu, Lihu
    Khadaroo, Parikshit Asutosh
    Su, Hui
    Kong, Liya
    Chen, Liangliang
    Wang, Xianfa
    Li, Xinlong
    Zhu, Hepan
    Zhong, Xin
    Pan, Junhai
    Chen, Manman
    [J]. BMC CANCER, 2019, 19 (1)
  • [2] COMBINED CHECKPOINT INHIBITORS (ANTI-PD-1/PD-L1 PLUS ANTI-CTLA4) INDUCED HEPATOTOXICITY: A SYSTEMATIC REVIEW AND META-ANALYSIS
    Karna, Rahul
    Deliwala, Smit S.
    Ramgopal, Balasubramanian
    Mishra, Rahul
    Grover, Dheera
    Kalra, Tanisha
    Bhalla, Jaideep Singh
    Saraswati, Ushasi
    Asawa, Palash
    Virk, Shiza T.
    Jayakrishnan, Thejus
    Mohan, Babu P.
    [J]. GASTROENTEROLOGY, 2022, 162 (07) : S702 - S703
  • [3] Hepatic and digestive adverse events of immune checkpoint inhibitors (anti-CTLA-4 and, anti-PD-1/PD-L1): A clinico-pathological review
    Papouin, Barbara
    Mussini, Charlotte
    De Martin, Eleonora
    Guettier, Catherine
    [J]. ANNALES DE PATHOLOGIE, 2018, 38 (06) : 338 - 351
  • [4] Efficacy and safety of anti-PD-1 and anti-PD-1 combined with anti-CTLA-4 immunotherapy to advanced melanoma: A systematic review and meta-analysis of randomized controlled trials
    Hao, Chunyan
    Tian, Jinhui
    Liu, Huiling
    Li, Fei
    Niu, Hongxia
    Zhu, Bingdong
    [J]. MEDICINE, 2017, 96 (26)
  • [5] Comprehensive Evaluation of Anti-PD-1, Anti-PD-L1, Anti-CTLA-4 and Their Combined Immunotherapy in Clinical Trials: A Systematic Review and Meta-analysis
    Xiang, Ze
    Li, Jiayuan
    Zhang, Zhengyu
    Cen, Chao
    Chen, Wei
    Jiang, Bin
    Meng, Yiling
    Wang, Ying
    Berglund, Bjoern
    Zhai, Guanghua
    Wu, Jian
    [J]. FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [6] Combination immunotherapy using anti-PD-1/PD-L1 plus anti-CTLA-4 antibodies
    Reck, Martin
    [J]. ANNALS OF ONCOLOGY, 2021, 32 : S249 - S249
  • [7] Safety and Efficacy of Anti-PD-1/PD-L1 Inhibitors Compared With Docetaxel for NSCLC: A Systematic Review and Meta-Analysis
    Ma, Long
    Jin, Gang
    Yao, Keying
    Yang, Yi
    Chang, Ruitong
    Wang, Wenhao
    Liu, Jiawei
    Zhu, Zijiang
    [J]. FRONTIERS IN PHARMACOLOGY, 2021, 12
  • [8] Efficacy and Safety of PD-1/PD-L1 Checkpoint Inhibitors versus Anti-PD-1/PD-L1 Combined with Other Therapies for Tumors: A Systematic Review
    Zhang, Yiru
    Yao, Qigu
    Pan, Yong
    Fang, Xinru
    Xu, Haoying
    Zhao, Tingxiao
    Zhu, Guangqi
    Jiang, Tianan
    Li, Shibo
    Cao, Hongcui
    [J]. CANCERS, 2023, 15 (03)
  • [9] Opportunistic autoimmune disorcers potentiated by immune-checkpoint inhibitors anti-CTLA-4 and anti-PD-1
    Kong, Yi-chi M.
    Flynn, Jeffrey C.
    [J]. FRONTIERS IN IMMUNOLOGY, 2014, 5
  • [10] PD-L1 is a biomarker of real-world clinical outcomes for anti-CTLA-4 plus anti-PD-1 or anti-PD-1 monotherapy in metastatic melanoma
    Ellebaek, Eva
    Khan, Shawez
    Bastholt, Lars
    Schmidt, Henrik
    Haslund, Charlotte Aaquist
    Donia, Marco
    Svane, Inge Marie
    [J]. EUROPEAN JOURNAL OF CANCER, 2024, 198
12345